Tokyo Tape
Sign in
← GNI Group

Quarterly report · Q3

2160.TEDINET S100PN1P
Period2022-01-01 → 2022-09-30
Filed2022-11-14
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 62
MetricValuePeriodScopeSource row
Revenue¥12.8bn2022-01-01 → 2022-09-30Cons.Revenue IFRS
Revenue¥4.6bn2022-07-01 → 2022-09-30dCons.Revenue IFRS
Revenue¥12.7bn2021-01-01 → 2021-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥9.5bn2021-01-01 → 2021-09-30Cons.Revenue IFRS
Revenue¥3.1bn2021-07-01 → 2021-09-30dCons.Revenue IFRS
Operating income¥1.5bn2022-01-01 → 2022-09-30Cons.Operating profit loss IFRS
Operating income¥490m2022-07-01 → 2022-09-30dCons.Operating profit loss IFRS
Operating income¥2.0bn2021-01-01 → 2021-09-30Cons.Operating profit loss IFRS
Operating income¥505m2021-07-01 → 2021-09-30dCons.Operating profit loss IFRS
Profit before tax¥1.2bn2022-01-01 → 2022-09-30Cons.Profit loss before tax IFRS
Profit before tax¥433m2022-07-01 → 2022-09-30dCons.Profit loss before tax IFRS
Profit before tax¥1.1bn2021-01-01 → 2021-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥1.6bn2021-01-01 → 2021-09-30Cons.Profit loss before tax IFRS
Profit before tax¥371m2021-07-01 → 2021-09-30dCons.Profit loss before tax IFRS
Net income (owners)¥1.1bn2022-01-01 → 2022-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥400m2022-07-01 → 2022-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥1.1bn2021-01-01 → 2021-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥1.3bn2021-01-01 → 2021-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥353m2021-07-01 → 2021-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income¥324m2022-01-01 → 2022-09-30Cons.Profit loss IFRS
Net income¥126m2022-07-01 → 2022-09-30dCons.Profit loss IFRS
Net income¥55m2021-01-01 → 2021-12-31Cons.Profit loss IFRS (5-year summary)
Net income¥875m2021-01-01 → 2021-09-30Cons.Profit loss IFRS
Net income¥130m2021-07-01 → 2021-09-30dCons.Profit loss IFRS
Total assets¥36.5bnat 2022-09-30Cons.Assets IFRS
Total assets¥30.3bnat 2021-12-31Cons.Assets IFRS
Total assets¥29.8bnat 2021-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥14.4bnat 2022-09-30Cons.Liabilities IFRS
Total liabilities¥11.0bnat 2021-12-31Cons.Liabilities IFRS
Net assets / equity¥22.0bnat 2022-09-30Cons.Equity IFRS
Net assets / equity¥19.3bnat 2021-12-31Cons.Equity IFRS
Net assets / equity¥19.4bnat 2021-09-30Cons.Equity IFRS
Net assets / equity¥12.8bnat 2020-12-31dCons.Equity IFRS
Equity (owners)¥22.9bnat 2022-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥18.9bnat 2021-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥18.5bnat 2021-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥12.7bnat 2022-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥14.4bnat 2021-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥13.9bnat 2021-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥10.3bnat 2020-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow−¥163m2022-01-01 → 2022-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥552m2021-01-01 → 2021-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥755m2021-01-01 → 2021-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥2.9bn2022-01-01 → 2022-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥261m2021-01-01 → 2021-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥884m2021-01-01 → 2021-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥299m2022-01-01 → 2022-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥2.9bn2021-01-01 → 2021-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥3.2bn2021-01-01 → 2021-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥22.672022-01-01 → 2022-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥8.422022-07-01 → 2022-09-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥22.722021-01-01 → 2021-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥27.692021-01-01 → 2021-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥7.442021-07-01 → 2021-09-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥22.462022-01-01 → 2022-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥8.282022-07-01 → 2022-09-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥22.082021-01-01 → 2021-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥26.872021-01-01 → 2021-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥7.322021-07-01 → 2021-09-30dCons.Diluted earnings loss per share IFRS
Equity ratio62.8%at 2022-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio62.3%at 2021-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio62.1%at 2021-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 26
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-01-01 → 2022-09-30−¥38m
Reconciling Itemsreconcilingrevenue intersegment2022-01-01 → 2022-09-30−¥38m
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentrevenue2022-01-01 → 2022-09-30¥1.8bn
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentrevenue external2022-01-01 → 2022-09-30¥1.7bn
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentrevenue intersegment2022-01-01 → 2022-09-30¥38m
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentsegment profit2022-01-01 → 2022-09-30¥699m
jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segmentrevenue2022-01-01 → 2022-09-30¥11.0bn
jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segmentrevenue external2022-01-01 → 2022-09-30¥11.0bn
jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segmentsegment profit2022-01-01 → 2022-09-30¥796m
—segment totalrevenue2022-01-01 → 2022-09-30¥12.8bn
—segment totalrevenue external2022-01-01 → 2022-09-30¥12.8bn
—segment totalrevenue intersegment2022-01-01 → 2022-09-30¥38m
—segment totalsegment profit2022-01-01 → 2022-09-30¥1.5bn
Reconciling Itemsreconcilingrevenue2021-01-01 → 2021-09-30−¥35m
Reconciling Itemsreconcilingrevenue intersegment2021-01-01 → 2021-09-30−¥35m
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentrevenue2021-01-01 → 2021-09-30¥1.5bn
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentrevenue external2021-01-01 → 2021-09-30¥1.5bn
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentrevenue intersegment2021-01-01 → 2021-09-30¥35m
jpcrp040300-q3r_E05712-000Medical Devicereportable segmentsegment profit2021-01-01 → 2021-09-30¥547m
jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segmentrevenue2021-01-01 → 2021-09-30¥8.1bn
jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segmentrevenue external2021-01-01 → 2021-09-30¥8.1bn
jpcrp040300-q3r_E05712-000Pharmaceuticalreportable segmentsegment profit2021-01-01 → 2021-09-30¥1.4bn
—segment totalrevenue2021-01-01 → 2021-09-30¥9.6bn
—segment totalrevenue external2021-01-01 → 2021-09-30¥9.5bn
—segment totalrevenue intersegment2021-01-01 → 2021-09-30¥35m
—segment totalsegment profit2021-01-01 → 2021-09-30¥2.0bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 716
ItemContextValueUnit
Cash flows from used in financing activities IFRS (5-year summary)Prior1YTDDuration3176682000JPY
Cash flows from used in financing activities IFRS (5-year summary)CurrentYTDDuration-299280000JPY
Cash flows from used in financing activities IFRS (5-year summary)Prior1YearDuration2853211000JPY
Cash and cash equivalents IFRS (5-year summary)Prior1QuarterInstant13945474000JPY
Cash and cash equivalents IFRS (5-year summary)CurrentQuarterInstant12722213000JPY
Cash and cash equivalents IFRS (5-year summary)Prior1YearInstant14352133000JPY
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember47487843
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember47487843
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant47487843
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant47487843
Number of shares issued shares voting rightsCurrentQuarterInstant_SharesWithNoVotingRightsMember－
Number of shares issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember－
Number of shares issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember－
Number of voting rights issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember－
Number of shares issued shares voting rightsCurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember1300
Number of shares issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember47471400
Number of voting rights issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember474714
Number of shares issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember15143
Number of shares issued shares voting rightsCurrentQuarterInstant47487843
Number of voting rights issued shares voting rightsCurrentQuarterInstant474714
Number of shares held in own name treasury shares etcCurrentQuarterInstant_Row1Member1300
Total number of shares held treasury shares etcCurrentQuarterInstant_Row1Member1300
Shareholding ratio treasury shares etcCurrentQuarterInstant_Row1Member0.0000
Number of shares held in own name treasury shares etcCurrentQuarterInstant1300
Total number of shares held treasury shares etcCurrentQuarterInstant1300
Shareholding ratio treasury shares etcCurrentQuarterInstant0.0000
Property plant and equipment IFRSPrior1YearInstant2943602000JPY
Property plant and equipment IFRSCurrentQuarterInstant3993286000JPY
Right of use assets IFRSPrior1YearInstant865959000JPY
Right of use assets IFRSCurrentQuarterInstant844011000JPY
Goodwill IFRSPrior1YearInstant5020290000JPY
Goodwill IFRSCurrentQuarterInstant6299952000JPY
Intangible assets IFRSPrior1YearInstant2147671000JPY
Intangible assets IFRSCurrentQuarterInstant3033656000JPY
Deferred tax assets IFRSPrior1YearInstant180940000JPY
Deferred tax assets IFRSCurrentQuarterInstant218522000JPY
Other financial assets nca IFRSPrior1YearInstant951513000JPY
Other financial assets nca IFRSCurrentQuarterInstant2819227000JPY
Non current assets IFRSPrior1YearInstant12109978000JPY
Non current assets IFRSCurrentQuarterInstant17208656000JPY
Inventories ca IFRSPrior1YearInstant1382702000JPY
Inventories ca IFRSCurrentQuarterInstant1731618000JPY
Trade and other receivables ca IFRSPrior1YearInstant1885101000JPY
Trade and other receivables ca IFRSCurrentQuarterInstant3154160000JPY
Other financial assets ca IFRSPrior1YearInstant4743000JPY
Other financial assets ca IFRSCurrentQuarterInstant208443000JPY
Other current assets ca IFRSPrior1YearInstant562320000JPY
Other current assets ca IFRSCurrentQuarterInstant1431800000JPY
Cash and cash equivalents IFRSPrior1YearInstant14352133000JPY
Cash and cash equivalents IFRSCurrentQuarterInstant12722213000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2021-12-31pass
balance sheet identityconsolidated 2022-09-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2021-01-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-07-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-01-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-01-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-01-01/2021-09-30pass
statement vs summary · revenueconsolidated 2021-07-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-01-01/2022-09-30pass
statement vs summary · revenueconsolidated 2022-07-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2021-12-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass